Efficacy and safety of subcutaneous esketamine in the treatment of suicidality in major depressive disorder and bipolar depression - Surjan J, Grossi JD, Del Porto JA, Delfino RS, de Oliveira Cerqueira R, Lucchese AC, Magalh ães E, Del Sant LC, Tuena MA, Nakahira C, Fava VAR, Steglich MS, Abdo GL, Barbosa MG, Sarin LM, Lacerda ALT.

BACKGROUND AND OBJECTIVE: Affective disorders account for most cases of suicide. The pharmacological arsenal to treat suicidality is limited and available agents take too long to take effect. A large body of evidence shows optimal results of ketamine for t...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news